

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	1
SCOPE OF REPORT.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
AUTHOR'S CREDENTIALS.....	3
RELATED BCC WORK CREDENTIALS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL FORECAST OF THE KINASE</i>	
<i>INHIBITORS (RT, NRT, AND S/T) MARKET BY TYPE, THROUGH</i>	
<i>2014 (\$ MILLIONS).....</i>	<i>5</i>
<i>SUMMARY FIGURE GLOBAL FORECAST OF THE KINASE</i>	
<i>INHIBITORS MARKET BY TYPE, 2006–2014 (\$ MILLIONS).....</i>	<i>5</i>
 CHAPTER THREE: OVERVIEW.....	 6
THE CELLULAR ROLE OF KINASES.....	6
INHIBITORS OF PROTEIN KINASES.....	7
INHIBITORS OF PROTEIN KINASES (CONTINUED).....	8
KINASES AS ATTRACTIVE DRUG TARGETS.....	9
<i>TABLE 1 ATTRACTIVE FEATURES OF PROTEIN KINASES.....</i>	<i>10</i>
KINASE INHIBITORS IN CLINICAL USE AND CLINICAL TRIALS.....	10
<i>TABLE 2 FDA-APPROVED KINASE INHIBITORS.....</i>	<i>11</i>
<i>TABLE 3 KINASE INHIBITORS IN CLINICAL TRIALS, ORDERED BY</i>	
<i>PHASE.....</i>	<i>12</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>13</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>14</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>15</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>16</i>
<i>TABLE 3 (CONTINUED).....</i>	<i>17</i>
<i>TABLE 4 NUMBER OF KINASE INHIBITORS IN CLINICAL TRIALS,</i>	
<i>BY PHASE.....</i>	<i>17</i>
<i>TABLE 5 COMPANIES WITH KINASE INHIBITORS IN CLINICAL</i>	
<i>TRIALS.....</i>	<i>17</i>
<i>TABLE 5 (CONTINUED).....</i>	<i>18</i>
DATABASES AND LARGE-SCALE INITIATIVES.....	18
<i>TABLE 6 KINASE DATABASES.....</i>	<i>19</i>
KINBASE.....	19
KINASENET.....	19
KINASE SEQUENCE DATABASE (KSD).....	20

KINMUTBASE.....	21
SCANSITE.....	21
KINASE PATHWAY DATABASE.....	22
CHAPTER FOUR: TECHNOLOGY OVERVIEW .....	23
DEVELOPMENT PROCESS.....	23
TYPES OF KINASE INHIBITORS.....	24
TABLE 7 COMPARISON OF TYPES OF INHIBITORS.....	24
SMALL MOLECULE KINASE INHIBITORS.....	24
TABLE 8 COMPARISON OF ATP COMPETITIVE AND NONCOMPETITIVE INHIBITORS .....	25
ATP COMPETITIVE INHIBITORS.....	25
NON-ATP COMPETITIVE INHIBITORS .....	25
MONOCLONAL ANTIBODIES .....	26
ISSUES OF SPECIFICITY.....	27
ISSUES OF SPECIFICITY (CONTINUED) .....	28
PROTEIN STRUCTURE AND MODELING.....	29
RATIONAL DESIGN.....	30
CHAPTER FIVE: PATENT EVALUATION.....	31
PATENT SHARE BY KINASE TYPE.....	31
TABLE 9 KINASE INHIBITOR PATENTS BY TARGET MOLECULE, JULY 2006 TO JULY 2009 (NUMBER).....	31
TABLE 10 U.S. AND EU APPROVED KINASE INHIBITORS MAJOR PATENT/EXCLUSIVITY EXPIRATION DATES.....	32
TABLE 11 KINASE INHIBITOR PATENTS BY ASSIGNEE (NUMBER).....	32
TABLE 11 (CONTINUED).....	33
CHAPTER SIX: MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS.....	34
TOTAL MARKET SIZE .....	34
TABLE 12 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2014 (\$ MILLIONS).....	34
FIGURE 1 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, 2006–2014 (\$ MILLIONS) .....	35
RECEPTOR TYROSINE KINASE BIOLOGY.....	35
EGFR/HER FAMILY PROTEIN KINASES (EGFR, HER2, HER3, AND HER4) .....	36
OVERVIEW .....	36
TABLE 13 EGFR FAMILY INHIBITORS BY STAGE OF CLINIAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS).....	37
EGFR INHIBITORS IN CLINICAL USE .....	38
Erbbitux (Cetuximab).....	38
Erbbitux (Cetuximab) (Continued) .....	39

Tarceva (Erlotinib) .....	40
Tarceva (Erlotinib) (Continued) .....	41
Iressa (Gefitinib).....	42
FDA APPROVAL IN THE UNITED STATES .....	43
FAST TRACK APPROVAL IN JAPAN .....	44
POST-MARKET STUDIES OF IRESSA.....	45
Vectibix (Panitumumab) .....	46
Nimotuzumab .....	47
GLOBAL MARKET FOR EGFR INHIBITORS.....	47
<i>TABLE 14 GLOBAL MARKET FOR EGFR INHIBITORS BY REGION,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>47</i>
EGFR INHIBITORS IN DEVELOPMENT .....	48
Tovok (BIBW 2992).....	49
Neratinib (HKI-272) .....	49
Zactima (Vandetanib, ZD6474) .....	50
Zalutumumab (HuMax-EGFr) .....	51
IMC-11F8 .....	51
BMS-690514.....	52
HER2 INHIBITORS .....	52
IN CLINICAL USE .....	52
Herceptin (Trastuzumab).....	52
Tykerb/Tyverb (Lapatinib) .....	53
HER2 INHIBITORS IN CLINICAL DEVELOPMENT.....	54
ARRY-380.....	54
INSM-18.....	55
GLOBAL MARKET FOR HER2 INHIBITORS .....	55
<i>TABLE 15 GLOBAL MARKET FOR HER2 INHIBITORS BY REGION,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>55</i>
Global Market for HER2 Inhibitors (Continued) .....	56
VEGF RECEPTOR FAMILY INHIBITORS .....	57
OVERVIEW .....	57
<i>TABLE 16 VEGFR FAMILY INHIBITORS BY STAGE OF CLINICAL</i>	
<i>DEVELOPMENT (WITH TARGET(S) IN BRACKETS).....</i>	<i>58</i>
VEGF RECEPTOR INHIBITORS IN CLINICAL USE.....	58
Nexavar (Sorafenib).....	58
Sutent (Sunitinib).....	59
Palladia (Toceranib) .....	60
VEGFR INHIBITORS IN DEVELOPMENT .....	60
Axitinib (AG-013736).....	60
Motesanib (AMG 706).....	61
Recentin (Cediranib, AZD2171) .....	62
Vargatef (BIBF 1120) .....	63
Pazopanib (GW786034) .....	64
Ramucirumab (IMC-1121B).....	64

Vatalanib (PTK787, ZK222584).....	65
Brivanib (BMS-582664).....	66
XL184 (BMS-907351) .....	66
XL880 (GSK1363089).....	67
ABT-869 .....	68
GLOBAL MARKET FOR VEGFR INHIBITORS .....	68
TABLE 17 GLOBAL MARKET FOR VEGFR INHIBITORS BY REGION, THROUGH 2014 (\$ MILLIONS).....	68
PDGFR RECEPTOR FAMILY INHIBITORS .....	69
OVERVIEW .....	69
TABLE 18 PDGFR FAMILY INHIBITORS BY STAGE OF CLINIAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS).....	70
PDGFR FAMILY INHIBITORS IN DEVELOPMENT.....	71
Masitinib (AB1010).....	71
Tandutinib (MLN518, CT53518) .....	71
IMC-3G3.....	72
INS RECEPTOR FAMILY INHIBITORS.....	72
OVERVIEW .....	72
INS RECEPTOR FAMILY INHIBITORS IN DEVELOPMENT .....	73
Figitumumab (CP-751871, CP-751, 871).....	73
AMG-479 .....	73
CHAPTER SEVEN: MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS.....	
TOTAL MARKET SIZE AND BACKGROUND.....	74
TABLE 19 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET BY PRODUCT, THROUGH 2014 (\$ MILLIONS).....	74
FIGURE 2 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET, 2006–2014 (\$ MILLIONS) .....	75
ABL KINASES .....	76
OVERVIEW .....	76
ABL INHIBITORS IN CLINICAL USE.....	76
Gleevec .....	76
Tasigna (Nilotinib, AMN107).....	77
ABL INHIBITORS IN DEVELOPMENT.....	78
AT9283 .....	78
AP24534 .....	78
Bafetinib (INNO-406) .....	78
KW-2449.....	79
XL228 .....	79
GLOBAL MARKET FOR ABL INHIBITORS.....	79
TABLE 20 GLOBAL FORECAST FOR ABL INHIBITORS MARKET BY REGION, THROUGH 2014 (\$ MILLIONS) .....	79
Global Market for ABL Inhibitors (Continued).....	80
SRC KINASES .....	81

OVERVIEW .....	81
SRC KINASE INHIBITORS IN CLINICAL USE .....	82
Sprycel (Dasatinib, BMS-354825).....	82
SRC KINASE INHIBITORS IN DEVELOPMENT .....	83
Bosutinib (SKI-606).....	83
AZD0530 .....	84
KX2-391.....	84
JAK KINASES .....	85
OVERVIEW .....	85
JAK INHIBITORS IN DEVELOPMENT .....	86
CP-690.....	86
INCB18424 .....	86
INCB28050 .....	87
Lestaurtinib (CEP-701).....	87
ONX 0803 (SB1518).....	87
TG101348.....	88
FAKS .....	88
OVERVIEW .....	88
FAK INHIBITORS IN DEVELOPMENT .....	88
PF-00562271 .....	88
PF-04554878 .....	89
 CHAPTER EIGHT: MARKET FOR SERINE/THREONINE KINASE	
INHIBITORS.....	90
TOTAL MARKET SIZE .....	90
<i>TABLE 21 GLOBAL FORECAST FOR THE STKI MARKET BY</i>	
<i>PRODUCT, THROUGH 2014 (\$ MILLIONS)</i> .....	90
<i>FIGURE 3 GLOBAL FORECAST FOR THE STKI MARKET, 2006–2014</i>	
<i>(\$ MILLIONS)</i> .....	91
MTOR KINASE INHIBITORS .....	91
OVERVIEW .....	91
MTOR INHIBITORS IN CLINICAL USE .....	92
Rapamune (Sirolimus).....	92
Certican, Afinitor (Everolimus, RAD001).....	92
Certican, Afinitor (Everolimus, RAD001)	
(Continued) .....	93
Torisel (Temsirolimus) .....	94
GLOBAL MARKET FOR MTOR INHIBITORS .....	94
<i>TABLE 22 GLOBAL MARKET FOR MTOR INHIBITORS* BY REGION,</i>	
<i>THROUGH 2014 (\$ MILLIONS)</i> .....	95
IN DEVELOPMENT .....	96
Ridaforolimus, Deforolimus (MK-8669, AP23573).....	96
AZD8055 .....	96
BEZ235.....	96
BGT226 .....	97

OSI-027 .....	97
PF-04691502 .....	97
XL765 .....	97
RHO FAMILY KINASE INHIBITORS .....	98
OVERVIEW .....	98
RHO KINASE FAMILY INHIBITORS IN CLINICAL USE.....	98
Eril (Fasudil Hydrochloride) .....	98
RHO KINASE FAMILY INHIBITORS IN DEVELOPMENT.....	99
Cethrin (BA-210) .....	99
SAR407899A .....	99
DE-104 .....	99
Y-39983, RKI-983 .....	99
GLOBAL MARKET FOR RHO-KINASE INHIBITORS .....	99
<i>TABLE 23 GLOBAL MARKET FOR RHO-KINASE INHIBITORS BY</i>	
<i>REGION, THROUGH 2014 (\$ MILLIONS) .....</i>	<i>100</i>
CYCLIN DEPENDENT KINASES .....	101
OVERVIEW .....	101
CDK INHIBITORS IN CLINICAL DEVELOPMENT.....	101
Alvocidib (Flavopiridol, HMR1275) .....	101
Seliciclib (CYC202, Roscovitine) .....	102
P276.....	103
AT7519 .....	103
PD-0332991.....	103
P1446.....	103
PROTEIN KINASE C .....	103
OVERVIEW .....	103
PKC INHIBITORS IN CLINICAL DEVELOPMENT .....	104
Enzastaurin (LY317615) .....	104
Midostaurin (PKC412) .....	105
Sotrastaurin (AEB071).....	105
KAI-9803 .....	106
KAI-1678 .....	107
PI3K.....	107
OVERVIEW .....	107
PI3 KINASE INHIBITORS IN CLINICAL DEVELOPMENT.....	108
AZD6482 .....	108
BKM120 .....	108
CAL-101 .....	108
CAL-263 .....	108
GDC-0941 (RG7321) .....	108
GDC-0980 (RG7422) .....	109
PX-866 .....	109
SF1126 .....	109
XL147 .....	109

AURORA KINASES.....	110
OVERVIEW .....	110
AURORA KINASE INHIBITORS IN CLINICAL DEVELOPMENT .....	110
AZD1152 .....	110
MLN8237 .....	110
PHA-739358.....	111
CYC116 .....	111
MK-5108 (VX-689) .....	111
R763 (AS703569) .....	111
SNS-314 .....	112
TAK-901 .....	112
MAP/MEK KINASES.....	112
OVERVIEW .....	112
MEK/P38 INHIBITORS IN CLINICAL DEVELOPMENT.....	113
AZD6244 .....	113
ARRY-797.....	114
BMS-582949.....	114
Losmapimod (GW856553) .....	114
JUN N-TERMINAL KINASES (JNK) .....	114
OVERVIEW .....	114
JNK INHIBITORS IN CLINICAL DEVELOPMENT .....	115
Perifosine (KRX-041).....	115
 CHAPTER NINE: MARKET FOR KINASE INHIBITORS BY DISEASE	
APPLICATION .....	116
TOTAL MARKET SIZE .....	116
<i>TABLE 24 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET     BY CURRENT APPLICATIONS, THROUGH 2014</i> .....	117
CURRENT APPLICATIONS.....	117
CANCER.....	117
Market Size by Kinase Inhibitors .....	117
<i>TABLE 25 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET     IN CANCER TREATMENT BY PRODUCT, THROUGH 2014 (\$     MILLIONS)</i> .....	117
<i>TABLE 26 KINASE INHIBITORS APPROVED TO TREAT CANCER     INDICATIONS</i> .....	118
Types of Cancer .....	119
Lung Cancer.....	119
EGFR Inhibitors for Lung Cancer Treatment.....	120
VEGFR Inhibitors for Lung Cancer .....	121
Breast Cancer.....	121
ERB/HER2 Inhibitors for Breast Cancer Treatment .....	122
Colorectal Cancer.....	122

EGFR Inhibitors for Colorectal Cancer.....	123
Pancreatic Cancer .....	123
EGFR Inhibitors for Pancreatic Cancer	
Treatment .....	124
Other Kinase Inhibitors for Pancreatic Cancer.....	125
Skin Cancers .....	125
Basal Cell Carcinoma .....	125
Squamous Cell Carcinoma .....	126
Melanoma .....	126
EGFR Inhibitors for Skin Cancer Treatment.....	127
MAPK/ERK Inhibitors for Skin Cancer	
Treatment .....	127
PI3K Inhibitors for Skin Cancer Treatment.....	127
Ras/Raf Inhibitors in Skin Cancer Treatment .....	128
Kidney Cancer.....	128
Kinase Inhibitors in Kidney Cancer.....	128
Sarcoma.....	129
Kinase Inhibitors for GIST.....	129
Liver Cancer.....	129
Kinase Inhibitors in Liver Cancer .....	130
Leukemias .....	130
Chronic Myeloid Leukemia .....	130
Acute Myeloid Leukemia.....	131
BCR-ABL Inhibitors for Leukemia Treatment .....	131
Flt3 Inhibitors for Leukemia Treatment .....	132
IMMUNE AND INFLAMMATORY DISEASES.....	133
MARKET SIZE BY KINASE INHIBITORS .....	133
<i>TABLE 27 WORLDWIDE MARKET FOR KINASE INHIBITORS IN</i>	
<i>IMMUNE AND INFLAMMATORY DISEASE BY PRODUCT,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>133</i>
Immunosuppression for Organ Transplantation .....	134
mTOR Inhibitors for Immunosuppression .....	134
Asthma .....	135
MAPK Inhibitors in Asthma Treatment.....	135
Arthritis .....	136
MAPK Inhibitors in Arthritis Treatment .....	137
CARDIOVASCULAR DISEASE.....	137
MARKET SIZE BY KINASE INHIBITORS .....	138
<i>TABLE 28 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET</i>	
<i>IN CARDIOVASCULAR DISEASE TREATMENT BY PRODUCT,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>138</i>
Rho Kinases for Cardiovascular Disease.....	138
MAPK Inhibitors for Cardiovascular Treatment .....	139
MAPK Inhibitors for ... (Continued) .....	140



MEK/MAPK1 Inhibitors for Cardiovascular Disease .....	141
JNK inhibitors for Cardiovascular disease .....	141
EMERGING APPLICATIONS .....	141
DIABETES .....	141
VEGF Inhibitors for Treatment of Diabetes .....	142
FLT3 Inhibitors for Treatment of Diabetes.....	142
PKC Inhibitors in the Treatment of Diabetes .....	143
MACULAR DEGENERATION.....	143
VEGF Inhibitors for Macular Degeneration.....	144
NEUROLOGICAL DISEASE.....	145
GSK Kinase Inhibitors for Neurological Disease.....	145
CDK Inhibitors for Neurological Disease .....	146
CHAPTER TEN: MAJOR COMPANIES AND MARKET SHARE.....	147
MARKET SHARES.....	147
<i>TABLE 29 KINASE INHIBITOR SALES AND MARKET SHARE OF</i>	
<i>COMPANIES INVOLVED IN KINASE INHIBITORS, 2008 (\$</i>	
<i>MILLIONS/%).....</i>	<i>147</i>
<i>TABLE 30 SALES AND MARKET SHARE OF COMPANIES INVOLVED</i>	
<i>IN TKI, 2008 (\$ MILLIONS/%).....</i>	<i>148</i>
COMPANY PROFILES .....	148
AB SCIENCE.....	149
AB Science USA.....	149
AMGEN .....	149
ARIAD PHARMACEUTICALS.....	150
ARRAY BIOPHARMA.....	150
ASTEX THERAPEUTICS.....	151
ASTRAZENECA .....	151
Astrazeneca – U.S. Headquarters.....	151
AVEO PHARMACEUTICALS .....	152
BAYER AG .....	153
Bayer – U.S. Location.....	153
BOEHRINGER INGELHEIM .....	154
Boehringer Ingelheim Pharmaceuticals, Inc.....	154
BRISTOL-MYERS SQUIBB .....	154
CEPHALON, INC.....	155
CYCLACEL PHARMACEUTICALS .....	156
Cyclacel – U.S. Location .....	156
ELI LILLY .....	157
EXELIXIS .....	158
GENMAB.....	158
Genmab – U.S. Location.....	158
GLAXOSMITHKLINE .....	159
GlaxoSmithKline – U.S. Location.....	159
INCYTE .....	160

KAI PHARMACEUTICALS.....	160
MERCK KGAA (MERCK SERONO).....	161
NOVARTIS .....	162
Novartis Institutes for BioMedical Research, Inc. ....	162
ONYX PHARMACEUTICALS.....	163
OSI PHARMACEUTICALS .....	163
PFIZER .....	164
ROCHE (F. HOFFMANN-LA ROCHE, LTD.).....	165
SANOFI-AVENTIS .....	165
TAKEDA.....	166
TARGEEN .....	167
VERTEX PHARMACEUTICALS .....	167
WYETH.....	168

## CHAPTER ELEVEN: INTERNATIONAL ASPECTS AND REGULATORY

ISSUES .....	169
MARKET BY REGION .....	169
<i>TABLE 31 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET</i>	
<i>BY REGION, THROUGH 2014 (\$ MILLIONS)</i> .....	169
<i>FIGURE 4 REGIONAL SHARE OF GLOBAL MARKET FOR KINASE</i>	
<i>INHIBITORS, BY REGION 2008 AND 2014 (%)</i> .....	170
UNITED STATES.....	171
DRUG WITHDRAWALS.....	171
MEDICARE .....	171
OTHER HEALTHCARE CHANGES.....	172
EUROPEAN UNION .....	172
NEW DRUG APPROVALS AND INNOVATION .....	172
DRUG REIMBURSEMENT AND REFERENCE PRICING.....	173
RELOCATION OF R&D .....	174
REGULATORY CLIMATE .....	175
JAPAN.....	175
NEW DRUG APPROVALS .....	175
REGULATORY CLIMATE .....	175
RELATIONSHIP OF ACADEMIA AND INDUSTRY .....	176
VENTURE CAPITAL.....	177

## CHAPTER TWELVE: FUTURE DIRECTIONS..... 178

SPECIFICITY AND COMPLEXITY .....	178
RESISTANCE .....	179
KINASE ACTIVATORS.....	180
DEVELOPMENTS IN ENABLING TECHNOLOGIES.....	181
PHOSPHORYLATION-STATE ANTIBODIES .....	181
Phosphorylation-State Antibodies (Continued).....	182
HIGH-THROUGHPUT KINASE ASSAYS .....	183
HIGH-THROUGHPUT KINASE ASSAYS(CONT) .....	<a href="#">184</a>

